20/20 GeneSystems
Diagnostic Testing for COVID-19 & Cancer
Overview
Raised: $232,704
Total Commitments ($USD)
StartEngine
08/16/2022
12/21/2022
$9,995
$4,999,995
$500
Convertible Note
Series A
RegCF
$58,400,000
10%
Rolling Commitments ($USD)
12/31/2022
2,328%
5%
$1,832
160
2000
Healthcare & Pharmaceuticals
HealthTech
B2B/B2C
Medium
High
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$9,622,332 |
$2,330,528 |
|
COGS |
$4,927,374 |
$1,453,354 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$2,071,777 |
$-2,021,826 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$3,354,469 |
$3,468,192 |
|
Accounts Receivable |
$4,215,465 |
$205,071 |
|
Total Assets |
$10,272,281 |
$4,677,734 |
|
Short-Term Debt |
$0 |
$103,860 |
|
Long-Term Debt |
$0 |
$40,247 |
|
Total Liabilities |
$0 |
$144,107 |
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| 20/20 GeneSystems | 12/21/2022 | StartEngine | $58,400,000 | $232,704 | Convertible Note | Funded | RegCF |
| 20/20 GeneSystems | 06/27/2021 | StartEngine | $38,500,000 | $2,903,017 | Equity - Preferred | Funded | RegA+ |
| 20/20 GeneSystems | 11/01/2020 | SeedInvest | $38,500,000 | $3,792,229 | Equity - Preferred | Funded | RegA+ |
| 20/20 GeneSystems | 12/14/2017 | Microventures | $23,000,000 | $1,064,807 | Equity - Preferred | Funded | RegCF |
Upgrade to gain access
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Ratings 
Analyst Report
20/20 GeneSystems offers an affordable blood test that screens for multiple types of cancer. It also has access to the medical records of more than 200,000 patients with known cancer outcomes. Its testing technology and machine learning algorithms are innovative — but it’s not clear if there’s enough market demand for its product.